Pharma drops again in public opinion

It's not pleasant company at the bottom of this list. According to a new Harris Interactive poll, only 26 percent of Americans have a favorable view of the drug industry--a record that's even worse than Big Oil, and better only than tobacco companies. It's a low point, following a slow-but-steady decline in consumer opinion.

Fair? That's not the point. The question is, do drugmakers intend to do whatever it takes to reverse the trend? Or should they just accept the dubious honor? Given the challenges pharma faces these days, improving public opinion may not be number one on the priority list.

- find Harris Interactive's release
- check out the analysis at DTC Perspectives
- see the Pharmalot item

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.